MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
MCE 国际站:Anti-Blood Cancer Compound Library
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.MCE offers a unique collection of 2494 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.
Description & Advantages:
• A unique collection of 2494 compounds with identified and potential anti-blood cancer activity for high throughput screening (HTS) and high content screening (HCS).
• Targets include FLT3, Bcr-Abl, JAK, PI3K, PD-1/PD-L1, etc.
• A useful tool for the discovery of anti-blood cancer drugs.
• Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.
• Structurally diverse, medicinally active, and cell permeable.
• Detailed compound information with structure, IC50, and brief introduction.
• Validated NMR and HPLC to ensure high purity and quality.
• All compounds are in stock and continuously updated.